Bristol Myers (BMY) Reports Positive Colorectal Cancer Study Data
https://www.zacks.com/stock/news/2252898/bristol-myers-bmy-reports-positive-colorectal-cancer-study-data?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2252898
Apr 09, 2024 - Bristol Myers' (BMY) Krazati, in combination with cetuximab, demonstrates clinically meaningful activity as a targeted treatment option for patients with previously treated KRASG12C-mutated locally advanced or metastatic colorectal cancer.
0
Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress
https://www.zacks.com/stock/news/2251537/fate-therapeutics-fate-surges-86-4-ytd-on-pipeline-progress?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2251537
Apr 05, 2024 - Fate Therapeutics (FATE) gains 86.4% on encouraging pipeline progress of its cellular immunotherapies for cancer.
0
After Plunging -7.94% in 4 Weeks, Here's Why the Trend Might Reverse for Galapagos (GLPG)
https://www.zacks.com/stock/news/2249692/after-plunging-7-94-in-4-weeks-here-s-why-the-trend-might-reverse-for-galapagos-glpg?cid=CS-ZC-FT-tale_of_the_tape|rsi-2249692
Apr 03, 2024 - The heavy selling pressure might have exhausted for Galapagos (GLPG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
0
Bristol Myers (BMY) Wins EC Nod for Reblozyl Label Expansion
https://www.zacks.com/stock/news/2249839/bristol-myers-bmy-wins-ec-nod-for-reblozyl-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2249839
Apr 03, 2024 - Bristol Myers (BMY) receives European Commission's approval for a label expansion of Reblozyl (luspatercept) for another indication.
0
Novo Nordisk (NVO) Gets Positive CHMP Opinion for Insulin Icodec
https://www.zacks.com/stock/news/2245039/novo-nordisk-nvo-gets-positive-chmp-opinion-for-insulin-icodec?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2245039
Mar 22, 2024 - Novo Nordisk (NVO) receives a positive opinion from the CHMP for once-weekly basal insulin icodec for the treatment of diabetes in adults.
0
Bayer's (BAYRY) Elinzanetant Meets Goals in Third Phase III Study
https://www.zacks.com/stock/news/2243694/bayer-s-bayry-elinzanetant-meets-goals-in-third-phase-iii-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2243694
Mar 20, 2024 - Bayer's (BAYRY) pipeline candidate, elinzanetant, achieves primary and secondary goals in late-stage OASIS 3 study supporting submissions for marketing authorization.
0
Down -14.35% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a Turnaround
https://www.zacks.com/stock/news/2242089/down-14-35-in-4-weeks-here-s-why-galapagos-nv-glpg-looks-ripe-for-a-turnaround?cid=CS-ZC-FT-tale_of_the_tape|rsi-2242089
Mar 18, 2024 - Galapagos NV (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
0
FDA Rejects Amgen's (AMGN) NDA Seeking Full Nod for Lumakras
https://www.zacks.com/stock/news/2202718/fda-rejects-amgen-s-amgn-nda-seeking-full-nod-for-lumakras?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2202718
Dec 27, 2023 - Per the FDA, Amgen (AMGN) will need to complete an additional confirmatory study on Lumakras in certain lung cancer patients before February 2028 to secure full approval.
0
Sarepta (SRPT) Seeks Label Expansion for DMD Gene Therapy
https://www.zacks.com/stock/news/2202279/sarepta-srpt-seeks-label-expansion-for-dmd-gene-therapy?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2202279
Dec 26, 2023 - Sarepta (SRPT) files a supplement with the FDA seeking to expand its recently-approved gene therapy Elevidys' label to treat all DMD patients, regardless of age and ambulatory status.
0
Jazz Pharmaceuticals' (JAZZ) PTSD Drug Misses Study Goals
https://www.zacks.com/stock/news/2201716/jazz-pharmaceuticals-jazz-ptsd-drug-misses-study-goals?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2201716
Dec 22, 2023 - After a mid-stage study fails to show any improvement in its primary or secondary endpoints, Jazz (JAZZ) plans to scrap the development of its PTSD drug.
0
Pages: 12
Page 1